SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Olema Pharmaceuticals, Inc. (OLMA) News

Track canonical SquawkNews coverage tagged to OLMA, Olema Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol OLMA Asset equity Sector Markets 90 days 9 Last 8.885 Updated Sep 11, 2026, 10:33 PM UTC Open live news feed
L Olema drops after hours on AstraZeneca Etcamah data Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser NEWS | Sep 11, 2026, 10:33 PM UTC L Olema Oncology reports inducement grants under Nasdaq Rule 5635(c)(4) Olema Oncology disclosed inducement grants under Nasdaq Listing Rule 5635(c)(4). EQUITY | Sep 02, 2026, 08:30 PM UTC L Olema Oncology to Participate in Upcoming Investor Conferences Olema Oncology to Participate in Upcoming Investor Conferences EQUITY | Aug 31, 2026, 08:38 PM UTC L OLMA - Olema Oncology to Participate in Upcoming Investor Conferences OLMA - Olema Oncology to Participate in Upcoming Investor Conferences EQUITY | Aug 31, 2026, 08:30 PM UTC L OLMA Previewing SERENA-4 in 2H and its impact @ Piper OLMA Previewing SERENA-4 in 2H and its impact @ Piper EQUITY | Aug 20, 2026, 12:04 PM UTC L Olema Oncology appoints Jason O’Byrne as Chief Financial Officer Olema Oncology appoints Jason O’Byrne as Chief Financial Officer, according to TradeXchange Newsdesk. EQUITY | Aug 13, 2026, 11:01 AM UTC L Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59 Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ: OLMA ) with a Buy and lowers the price target from $62 to $59. EQUITY | Aug 11, 2026, 07:28 PM UTC L Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 Olema Pharmaceuticals Inc. (NASDAQ: OLMA ) shares are trading lower on Tuesday as the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in the first quarter of 2027. Addi EARNINGS | Aug 11, 2026, 06:27 PM UTC L OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of OppFi Inc (NYSE: OPFI ) fell sharply in pre-market trading after the company reported worse-than-expected EARNINGS | Aug 11, 2026, 12:04 PM UTC